Godwin Enwere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Godwin Enwere has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Adeola Vaughan
Medical Research Council Laboratories, Fajara, The Gambia
1 shared publicationAlieu Akano
National Hospital Abuja, Abuja, Nigeria
1 shared publication- Annelies Wilder-Smith
World Health Organization, CH-1211 Geneva, Switzerland
1 shared publication - Birgitte Giersing
World Health Organization, Geneva, Switzerland
1 shared publication Brian Greenwood
London School of Hygiene & Tropical Medicine, London, UK
1 shared publicationClaire Oluwalana
Medical Research Council Laboratories, Fajara, The Gambia
1 shared publication
Latest Publications
- Open Access
WHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries
Infectious diarrhea caused by Shigella remains a significant global health concern, and several vaccine candidates are approaching phase III clinical studies in the target population of young children in low- and middle-income countries. The World Health Organization (WHO) has published preferred product characteristics (PPCs) for Shigella vaccines to provide strategic guidance that aids in advancing product development and highlights policy considerations for use in LMIC settings where the vaccine is most needed. However, the selection of appropriate clinical endpoints was not clearly defined within the PPCs and remains an important issue for phase III study design. Previously, an expert panel identified areas of alignment and consensus on many clinical study design components while also recognizing that further discussions and data were required to solidify recommendations on key study design aspects. Therefore, WHO convened a diverse range of stakeholders, including manufacturers, regulators, and policymakers across national, regional, and global levels, with the aim of achieving consensus and soliciting inputs from the regulatory community surrounding vaccine phase III study design considerations. The intent of this report is to outline the key points from those discussions to inform the phase III design strategies and investment decisions of product developers and donors and to share recommendations for next steps.
Open AccessWHO Workshop Report: Regulatory Science to Inform Clinical Pathways for Shigella Vaccines Intended for Use in Children in Low- and Middle-Income Countries
Infectious diarrhea caused by Shigella remains a significant global health concern, and several vaccine candidates are approaching phase III clinical studies in the target population of young children in low- and middle-income countries. The World Health Organization (WHO) has published preferred product characteristics (PPCs) for Shigella vaccines to provide strategic guidance that aids in advancing product development and highlights policy considerations for use in LMIC settings where the vaccine is most needed. However, the selection of appropriate clinical endpoints was not clearly defined within the PPCs and remains an important issue for phase III study design. Previously, an expert panel identified areas of alignment and consensus on many clinical study design components while also recognizing that further discussions and data were required to solidify recommendations on key study design aspects. Therefore, WHO convened a diverse range of stakeholders, including manufacturers, regulators, and policymakers across national, regional, and global levels, with the aim of achieving consensus and soliciting inputs from the regulatory community surrounding vaccine phase III study design considerations. The intent of this report is to outline the key points from those discussions to inform the phase III design strategies and investment decisions of product developers and donors and to share recommendations for next steps.
- 28 November 2007
- Published by Wiley in Tropical Medicine & International Health
- Vol. 12 (11) , 1377-1385
Epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children
Summary: Objective To assess the effect of vaccines against pneumonia in Gambian children.Methods Data from a randomized, controlled trial of a 9‐valent pneumococcal conjugate vaccine (PCV) were used. Radiographic findings, interpreted using WHO definitions, were classified as primary end point pneumonia, ‘other infiltrates/abnormalities’ pneumonia and pneumonia with no abnormality. We calculated the incidence of the different types of radiological pneumonia, and compared clinical and laboratory features between these groups.Results Among children who did not receive PCV, the incidence of pneumonia with no radiographic abnormality was about twice that of ‘other infiltrates’ pneumonia and three times that of primary endpoint pneumonia. Most respiratory symptoms, reduced feeding and vomiting occurred most frequently in children with primary endpoint pneumonia. These children were more likely to be malnourished, to have bronchial breath sounds or invasive bacterial diseases, and to die within 28 days of consultation than children in the other groups. Conversely, a history of convulsion, diarrhoea or fast breathing, malaria parasitaemia and isolation of salmonellae were commoner in children with pneumonia with no radiographic abnormality. Lower chest wall indrawing and rhonchi on auscultation were seen most frequently in children with ‘other infiltrates/abnormalities’ pneumonia.Conclusion Primary endpoint pneumonia is strongly associated with bacterial aetiology and severe pneumonia. Since this category of pneumonia is significantly reduced after vaccination with Hib and pneumococcal vaccines, the risk‐benefit of antimicrobial prescription for clinical pneumonia for children with increased respiratory rate may warrant re‐examination once these vaccines are in widespread use.
- 28 November 2007
- Published by Wiley in Tropical Medicine & International Health
- Vol. 12 (11) , 1377-1385
Epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children
Summary: Objective To assess the effect of vaccines against pneumonia in Gambian children.Methods Data from a randomized, controlled trial of a 9‐valent pneumococcal conjugate vaccine (PCV) were used. Radiographic findings, interpreted using WHO definitions, were classified as primary end point pneumonia, ‘other infiltrates/abnormalities’ pneumonia and pneumonia with no abnormality. We calculated the incidence of the different types of radiological pneumonia, and compared clinical and laboratory features between these groups.Results Among children who did not receive PCV, the incidence of pneumonia with no radiographic abnormality was about twice that of ‘other infiltrates’ pneumonia and three times that of primary endpoint pneumonia. Most respiratory symptoms, reduced feeding and vomiting occurred most frequently in children with primary endpoint pneumonia. These children were more likely to be malnourished, to have bronchial breath sounds or invasive bacterial diseases, and to die within 28 days of consultation than children in the other groups. Conversely, a history of convulsion, diarrhoea or fast breathing, malaria parasitaemia and isolation of salmonellae were commoner in children with pneumonia with no radiographic abnormality. Lower chest wall indrawing and rhonchi on auscultation were seen most frequently in children with ‘other infiltrates/abnormalities’ pneumonia.Conclusion Primary endpoint pneumonia is strongly associated with bacterial aetiology and severe pneumonia. Since this category of pneumonia is significantly reduced after vaccination with Hib and pneumococcal vaccines, the risk‐benefit of antimicrobial prescription for clinical pneumonia for children with increased respiratory rate may warrant re‐examination once these vaccines are in widespread use.